Which path to follow? Utilizing proteomics to improve therapy choices for breast cancer patients.
作者信息
Blucher Aurora S, Mills Gordon B, Tsang Yiu Huen
机构信息
Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
出版信息
Expert Rev Proteomics. 2020 Mar;17(3):187-190. doi: 10.1080/14789450.2020.1757442. Epub 2020 Apr 22.
Abstract
摘要
相似文献
1
Which path to follow? Utilizing proteomics to improve therapy choices for breast cancer patients.该遵循哪条路径？利用蛋白质组学改善乳腺癌患者的治疗选择。
Expert Rev Proteomics. 2020 Mar;17(3):187-190. doi: 10.1080/14789450.2020.1757442. Epub 2020 Apr 22.
2
How may targeted proteomics complement genomic data in breast cancer?靶向蛋白质组学如何补充乳腺癌中的基因组数据？
Expert Rev Proteomics. 2017 Jan;14(1):43-54. doi: 10.1080/14789450.2017.1256776. Epub 2016 Nov 15.
3
Proteomic classification of breast cancer.乳腺癌的蛋白质组学分类。
Curr Drug Targets. 2012 Nov;13(12):1495-509. doi: 10.2174/138945012803530080.
4
Implications of functional proteomics in breast cancer.功能蛋白质组学在乳腺癌中的意义
Oncologist. 2014 Apr;19(4):328-35. doi: 10.1634/theoncologist.2013-0437. Epub 2014 Mar 24.
5
Role of Proteomics in the Development of Personalized Medicine.蛋白质组学在个性化医疗发展中的作用。
Adv Protein Chem Struct Biol. 2016;102:41-52. doi: 10.1016/bs.apcsb.2015.09.002. Epub 2015 Nov 11.
6
Subtyping of breast cancer using reverse phase protein arrays.利用反相蛋白质阵列对乳腺癌进行亚型分类。
Expert Rev Proteomics. 2014 Dec;11(6):757-70. doi: 10.1586/14789450.2014.971113.
7
Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.评估基于反相蛋白质阵列（RPPA）的通路激活谱分析在84种非小细胞肺癌（NSCLC）细胞系中作为癌症蛋白质组学和生物标志物发现平台的作用。
Biochim Biophys Acta. 2014 May;1844(5):950-9. doi: 10.1016/j.bbapap.2013.11.017. Epub 2013 Dec 19.
8
Precision Medicine and Targeted Therapies in Breast Cancer.精准医学与乳腺癌的靶向治疗
Surg Oncol Clin N Am. 2020 Jan;29(1):51-62. doi: 10.1016/j.soc.2019.08.004. Epub 2019 Oct 29.
9
The Dawning of Translational Breast Cancer: From Bench to Bedside.从基础到临床：转化乳腺癌的曙光
Adv Exp Med Biol. 2017;1026:1-25. doi: 10.1007/978-981-10-6020-5_1.
10
RPPA: Origins, Transition to a Validated Clinical Research Tool, and Next Generations of the Technology.免疫组织化学染色蛋白质芯片分析（RPPA）：起源、向经验证的临床研究工具的转变，以及该技术的新一代。
Adv Exp Med Biol. 2019;1188:1-19. doi: 10.1007/978-981-32-9755-5_1.
引用本文的文献
1
The Breast Cancer Proteome and Precision Oncology.乳腺癌蛋白质组学与精准肿瘤学。
Cold Spring Harb Perspect Med. 2023 Oct 3;13(10):a041323. doi: 10.1101/cshperspect.a041323.
Zotero 插件